About this trial
AKI(Acute Kidney Injury) is a common complication after cardiac surgery which is associated with increased mortality and morbidity. Collecting perioperative biosignal data and studying their association with renal outcomes can help improve kidney injury, mortality, and morbidity in cardiac surgical patients. Furthermore, the occurrence of AKI, length of hospital stay, and recovery of renal function after discharge are closely associated with the development of chronic kidney disease (CKD). Therefore, regular monitoring of renal function and related indicators in cardiac surgical patients can help improve long-term outcomes.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Aged 19 years and older scheduled for cardiac surgery using CPB
Disqualifiers
emergency operation, the patient is foreigner or illiterate and unable to read the consent form
Trial population
Patients aged 19 year and older admitted to Severance cardiovascular hospital for cardiac surgery using CPB (Cardiopulmonary bypass).
Trial design
Cohort
Prospective
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
post-operative AKI incidence within 1 week after cardiac surgery with CPB
The definition of AKI refers to Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury.
Secondary outcomes
MAKE 30 (Major adverse kidney event within 30 days)
death, starting dialysis, or decrease in eGFR of 25 % or more within 30 days after surgery
MAKE 90 (Major Adverse kidney event within 90 days)
death, starting dialysis, or decrease in eGFR of 25 % or more within 90 days after surgery
incidence of CKD (chronic kidney disease) within 1 year
at least one of the following criteria is met, with structural or functional abnormalities of the kidney persisting for at least 3 months within 1 year * urine albumin/creatinine ratio ≥ 30 mg/g * abnormality in urine sediment test or persistent hematuria * renal structural abnormalities found in image study * eGFR \< 60 ml/min/1.73m2 (GFR category G3a-G5)
1 year mortality
death due to any cause within 1 year
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: